Insights

At the 2023 EHA Congress, Vincent Ribrag, MD, participated in a debate regarding if BTK inhibitors should be combined with other therapies such as bendamustine and rituximab as first-line treatment for mantle cell lymphoma.

At the 2023 ASCO annual meeting, Swetha Kambhampati, MD, provided insights into the real-world outcomes of brexucabtagene autoleucel therapy for patients with relapsed/refractory MCL through a subgroup analysis of outcomes by prior treatment.

At the 2023 ASCO annual meeting, Won Jin Jeon, MD, presented data from a meta-analysis that explored the prognostic value of identifying BCL6 and CD10 variants in the treatment and management of mantle cell lymphoma.

Lorenzo Falchi, MD presents extended follow-up from a pivotal phase 2 study on CD20-CD3 bispecific antibody glofitamab monotherapy for patients with R/R DLBCL.

James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.